Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Rastislav, Bahleda"'
Autor:
Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, Sylvain Briand, Andrea Cavalcanti, Ali N. Chamseddine, Charles Court, Elie Fadel, Matthieu Faron, Leila Haddag‐Miliani, Clémence Henon, Cécile Le Pechoux, Antonin Levy, Olaf Mercier, Carine Ngo, Charles Honoré, Axel Le Cesne, Olivier Mir
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3160-3166 (2023)
Abstract Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single‐agent in a larger series of patients with advanced angiosarcoma. We retrospectivel
Externí odkaz:
https://doaj.org/article/778e03d4ac564846b7db152411c47d9f
Autor:
Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-14 (2022)
Abstract Background We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors (PEMBIB trial; NC
Externí odkaz:
https://doaj.org/article/cc022ab82e6e4fd69d684a17c4dfa3ff
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Anti-PD-(L)1 therapies yield a disappointing response rate of 15% across soft-tissue sarcomas, even if some subtypes benefit more than others. The proportions of TAMs and TILs in their tumor microenvironment are variable, and this heterogeneity corre
Externí odkaz:
https://doaj.org/article/1248dc30b3184f279cfa2382cd0ba3da
Autor:
Jean‐Marie Michot, Cyril Quivoron, Clémentine Sarkozy, Alina Danu, Julien Lazarovici, Khalil Saleh, Yolla El‐Dakdouki, Vincent Goldschmidt, Camille Bigenwald, Matteo Dragani, Rastislav Bahleda, Capucine Baldini, Julia Arfi‐Rouche, Patricia Martin‐Romano, Lambros Tselikas, Anas Gazzah, Antoine Hollebecque, Ludovic Lacroix, David Ghez, Veronique Vergé, Christophe Marzac, Sophie Cotteret, Wassila Rahali, Jean‐Charles Soria, Christophe Massard, Olivier A. Bernard, Peggy Dartigues, Valérie Camara‐Clayette, Vincent Ribrag
Publikováno v:
American Journal of Hematology. 98:645-657
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83c09f85453cac881c334c43ddbe2644
https://doi.org/10.1002/ajh.26835
https://doi.org/10.1002/ajh.26835
Autor:
Sylvie Négrier, David Pérol, Rastislav Bahleda, Antoine Hollebecque, Etienne Chatelut, Helen Boyle, Philippe Cassier, Séverine Metzger, Ellen Blanc, Jean-Charles Soria, Bernard Escudier
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinas
Externí odkaz:
https://doaj.org/article/46c1a5aa646b4b408db58308c4011d25
Autor:
Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, Sylvain Briand, Andrea Cavalcanti, Ali N. Chamseddine, Charles Court, Elie Fadel, Matthieu Faron, Leila Haddag‐Miliani, Clémence Henon, Cécile Le Pechoux, Antonin Levy, Olaf Mercier, Carine Ngo, Charles Honoré, Axel Le Cesne, Olivier Mir
Publikováno v:
Cancer Medicine. 12:3160-3166
Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single-agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68b68f9262fa909ddeb95224a7239ef3
https://doi.org/10.1002/cam4.5147
https://doi.org/10.1002/cam4.5147
Autor:
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, Christophe Massard
This file provides supplementary methods for genomics, including TGS, CGH array, WES, RNAseq Analysis, IHC -MET.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba69ab65891380197866f102bd630ba
https://doi.org/10.1158/2159-8290.22532263.v1
https://doi.org/10.1158/2159-8290.22532263.v1
Autor:
Suso J. Platero, Matthew V. Lorenzi, John D. Alvarez, Feng R. Luo, Rastislav Bahleda, Michael Sharp, Peter King, Christopher H. Moy, Ademi Santiago-Walker, Joseph C. Portale, Dana Gaffney, Katherine Bell, Gabriela Martinez Cardona, Jayaprakash D. Karkera
Table S1. Frequencies of gene locus amplifications across tumor types; Table S2. Effect of FGFR inhibitors on growth of RK3E expressing FGFR2 and FGFR3 fusion constructs and RT-4 bladder cancer cell line; Figure S1. Chemical structure of JNJ-42756493
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21185a261e660d5f3fddafc34f8f11ec
https://doi.org/10.1158/1535-7163.22509070
https://doi.org/10.1158/1535-7163.22509070
Autor:
Lipika Goyal, Karim A. Benhadji, Yaohua He, Milind Javle, Joon Oh Park, Robin Kate Kelley, Ben Tran, Hendrik-Tobias Arkenau, John Bridgewater, Marc Sanson, Cinta Hierro, Rastislav Bahleda, Funda Meric-Bernstam
Supplementary Appendix including all supplementary tables and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785c6589354f41e2257c8de86a905508
https://doi.org/10.1158/2159-8290.22540240
https://doi.org/10.1158/2159-8290.22540240
Autor:
Lipika Goyal, Karim A. Benhadji, Yaohua He, Milind Javle, Joon Oh Park, Robin Kate Kelley, Ben Tran, Hendrik-Tobias Arkenau, John Bridgewater, Marc Sanson, Cinta Hierro, Rastislav Bahleda, Funda Meric-Bernstam
Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8247c1773432686e3fee1a82e6cd4db5
https://doi.org/10.1158/2159-8290.c.6549325.v1
https://doi.org/10.1158/2159-8290.c.6549325.v1